Paper29508136
A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer.
Elie BT and 3 others. J Biol Inorg Chem, 2018. Cited by 38 papers, by iCite.
Cite this record
ConductScience Library. A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer. Papers, record 29508136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29508136
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Renal Cell | Major topic |
| Cell Proliferation | Major topic |
| Coordination Complexes | Major topic |
| Gold | Major topic |
| Kidney Neoplasms | Major topic |
| Neoplasm Metastasis | Major topic |
| Neovascularization, Pathologic | Major topic |
| Protease Inhibitors | Major topic |
| Ruthenium Compounds | Major topic |
| Cell Line, Tumor | |
| Humans |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| SC1 CA182844 | NCI NIH HHS | United States | SC1CA182844 | PubMed and NIH |
Source NIH RePORTER
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19913918 | Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action. | J Inorg Biochem | 2010 | https://conductscience.org/library/papers/19913918 | PubMed |
| 2 | 25435644 | Organometallic Titanocene-Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties. | Organometallics | 2014 | https://conductscience.org/library/papers/25435644 | PubMed |
| 3 | 27467926 | Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/27467926 | PubMed |
| 4 | 25383481 | Auranofin, an anti-rheumatic gold compound, modulates apoptosis by elevating the intracellular calcium concentration ([ca2+]I) in mcf-7 breast cancer cells. | Cancers (Basel) | 2014 | https://conductscience.org/library/papers/25383481 | PubMed |
| 5 | 25367033 | Pericellular proteolysis in cancer. | Genes Dev | 2014 | https://conductscience.org/library/papers/25367033 | PubMed |
| 6 | 14661062 | Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. | Oncogene | 2004 | https://conductscience.org/library/papers/14661062 | PubMed |
| 7 | 26597527 | Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. | Nat Rev Cancer | 2015 | https://conductscience.org/library/papers/26597527 | PubMed |
| 8 | 17320769 | Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. | Free Radic Biol Med | 2007 | https://conductscience.org/library/papers/17320769 | PubMed |
| 9 | 20542334 | The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. | Leuk Res | 2011 | https://conductscience.org/library/papers/20542334 | PubMed |
| 10 | 27717148 | A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo. | Angew Chem Int Ed Engl | 2016 | https://conductscience.org/library/papers/27717148 | PubMed |
| 11 | 10620700 | The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts. | FEBS Lett | 2000 | https://conductscience.org/library/papers/10620700 | PubMed |
| 12 | 14647459 | Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. | Oncogene | 2003 | https://conductscience.org/library/papers/14647459 | PubMed |
| 13 | 25253202 | A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells. | Mol Cancer | 2014 | https://conductscience.org/library/papers/25253202 | PubMed |
| 14 | 28142080 | New copper(I) and heteronuclear copper(I)-ruthenium(II) complexes: Synthesis, structural characterization and cytotoxicity. | J Inorg Biochem | 2017 | https://conductscience.org/library/papers/28142080 | PubMed |
| 15 | 23786413 | Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights. | J Med Chem | 2013 | https://conductscience.org/library/papers/23786413 | PubMed |
| 16 | 28951461 | Inflammatory Monocytes Promote Perineural Invasion via CCL2-Mediated Recruitment and Cathepsin B Expression. | Cancer Res | 2017 | https://conductscience.org/library/papers/28951461 | PubMed |
| 17 | 21958150 | Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds. Studies of their interactions with DNA. | Inorg Chem | 2011 | https://conductscience.org/library/papers/21958150 | PubMed |
| 18 | 24637564 | Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity. | Nat Commun | 2014 | https://conductscience.org/library/papers/24637564 | PubMed |
| 19 | 21516419 | Cell migration and invasion assays. | Methods Mol Biol | 2011 | https://conductscience.org/library/papers/21516419 | PubMed |
| 20 | 16264276 | Up-regulation of defense enzymes is responsible for low reactive oxygen species in malignant prostate cancer cells. | Exp Mol Med | 2005 | https://conductscience.org/library/papers/16264276 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42193354 | Heterometallic Multinuclear Ruthenium Complexes as Cytotoxic Agents. | Biomedicines | 2026 | https://conductscience.org/library/papers/42193354 | PubMed |
| 41494918 | High Cytotoxicity of Ruthenium(II) and Gold(I) Bimetallic Complexes and Its Precursors. | Inorg Chem | 2026 | https://conductscience.org/library/papers/41494918 | PubMed |
| 41304972 | Review of the Most Important Research Trends in Potential Chemotherapeutics Based on Coordination Compounds of Ruthenium, Rhodium and Iridium. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41304972 | PubMed |
| 39200227 | Heteronuclear Complexes with Promising Anticancer Activity against Colon Cancer. | Biomedicines | 2024 | https://conductscience.org/library/papers/39200227 | PubMed |
| 38256884 | A Ru(II)-Strained Complex with 2,9-Diphenyl-1,10-phenanthroline Ligand Induces Selective Photoactivatable Chemotherapeutic Activity on Human Alveolar Carcinoma Cells via Apoptosis. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/38256884 | PubMed |
| 37727388 | Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37727388 | PubMed |
| 37507346 | Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast Cancer Models. | Chemistry | 2023 | https://conductscience.org/library/papers/37507346 | PubMed |
| 37332817 | Homobimetallic Au(I)-Au(I) and Heterotrimetallic Au(I)-Fe(II)-Au(I) Complexes with Dialkyldithiophosphates and Phosphine Ligands: Structural Characterization, DFT Analysis, and Tyrosinase Inhibitory and Biological Effects. | ACS Omega | 2023 | https://conductscience.org/library/papers/37332817 | PubMed |
| 37191319 | 5-Nitrofuryl-Containing Thiosemicarbazone Gold(I) Compounds: Synthesis, Stability Studies, and Anticancer Activity. | Chempluschem | 2023 | https://conductscience.org/library/papers/37191319 | PubMed |
| 37071737 | Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications. | Chem Rev | 2023 | https://conductscience.org/library/papers/37071737 | PubMed |
| 36615466 | Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments. | Molecules | 2022 | https://conductscience.org/library/papers/36615466 | PubMed |
| 36566618 | Promising heterometallic compounds as anticancer agents: Recent studies in vivo. | Curr Opin Chem Biol | 2023 | https://conductscience.org/library/papers/36566618 | PubMed |
| 35224494 | Ruthenium(ii)-arene complexes as anti-metastatic agents, and related techniques. | RSC Med Chem | 2022 | https://conductscience.org/library/papers/35224494 | PubMed |
| 35170871 | Metallodrugs: an approach against invasion and metastasis in cancer treatment. | FEBS Open Bio | 2022 | https://conductscience.org/library/papers/35170871 | PubMed |
| 34588987 | Gold Compounds and the Anticancer Immune Response. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34588987 | PubMed |
| 32832867 | Auranofin-Based Analogues Are Effective Against Clear Cell Renal Carcinoma In Vivo and Display No Significant Systemic Toxicity. | ACS Pharmacol Transl Sci | 2020 | https://conductscience.org/library/papers/32832867 | PubMed |
| 32695747 | Recent Advances of Gold Compounds in Anticancer Immunity. | Front Chem | 2020 | https://conductscience.org/library/papers/32695747 | PubMed |
| 32455715 | Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32455715 | PubMed |
| 32305711 | SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma. | J Chromatogr B Analyt Technol Biomed Life Sci | 2020 | https://conductscience.org/library/papers/32305711 | PubMed |
| 31192543 | Preclinical evaluation of an unconventional ruthenium-gold-based chemotherapeutic: RANCE-1, in clear cell renal cell carcinoma. | Cancer Med | 2019 | https://conductscience.org/library/papers/31192543 | PubMed |
Genes25
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29508136
GET https://conductscience.org/api/papers/v1/29508136/references?page=2